<DOC>
	<DOCNO>NCT01970046</DOCNO>
	<brief_summary>SP2086 new dipeptidy1 peptidase ( DPP ) -4 inhibitor . This study aim evaluate efficacy safety SP2086 combination therapy Metformin patient Type 2 Diabetes Mellitus Metformin monotherapy Who Have Inadequate Glycemic Control</brief_summary>
	<brief_title>A Phase III Study SP2086 Combination With Metformin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients diagnose type 2 diabetes mellitus subject metformin monotherapy stable dose ≥1500mg/d ≥8 week 7.5 % ≤HbA1C ≤11.0 % screening,7.0 % ≤HbA1C ≤10.5 % runin Body Mass Index : ≥19 ≤35 kg/m2 1 . ＜80 % ＞120 % compliance placebo treatment runin period 2 . Patients use follow drug therapy prior randomization : 1 ) Somatropin therapy within 6 month prior randomization 2 ) History drug alcohol abuse within 6 month prior randomization 3 ) Participate clinical trial drug medical device within 3 month prior randomization 4 ) Receive corticosteroid longterm ( 7 consecutive day ) oral , nongastrointestinal administration intraarticular administration within 2 month prior randomization 5 ) Weight control drug administration Surgeries result weight instability within 2 month prior randomization 6 ) In investigator 's opinion , patient use drug interfere assessment investigational product , produce vital organ toxicity 4 . Patients history follow disease proof prior randomization : 1 . Type 1 diabetes , single gene mutation diabetes , diabetes cause pancreatic damage secondary diabetes , cause Cushing 's syndrome acromegaly 2. history hypertension , antihypertensive treatment , systolic blood pressure ≥ 160 mmHg diastolic blood pressure ≥ 100 mmHg 3. history acute chronic pancreatitis pancreatic injury may lead high risk pancreatitis 4. serious haematological disease diseases lead hemolyze Red Blood Cell unstable ( malaria、haemolytic anaemia eg . ) 5. endocrine disease , example hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia 6 . Any organ system tumor except local skin basal cell carcinoma treat treat within 5 year prior randomization , regardless whether evidence local recurrence metastasis ; history family history medullary carcinoma thyroid ; history multiple endocrine neoplasia 7 . Decompensated heart failure ( NYHA class III IV ) , unstable angina , stroke transient ischemic attack , myocardial infarction , persistence clinical significance arrhythmia , coronary artery bypass graft percutaneous coronary intervention within 6 month prior randomization 8 . Acute metabolic complication ( ketoacidosis , lactic acidosis hyperosmolar coma ) , unstable proliferative retinopathy macular degeneration within 6 month prior randomization 9 . Severe trauma acute infection may affect blood glucose control within 4 week prior randomization 10 . Severe chronic gastrointestinal disease therapy may affect drug absorption , gastrointestinal surgery 11 . With history mental/emotional disorder would interfere subject 's participation study . 5 . Patients laboratory parameter meet follow criterion prior randomization : 1 . Aspartate Aminotransferase alanine aminotransferase ≥ 2.0× upper normal limit ( UNL ) , and/or total bilirubin ≥ 2.0 × UNL also review confirm within 3 day ; 2 . Triglyceride＞5.64mmol/L（500mg/dl）； 3. serum creatinine exceed normal range 4. thyroid stimulate hormone exceed normal range , clinical significance 5. blood amylase exceed normal range , clinical significance 6 . In investigator 's opinion , significant laboratory abnormality clinical significance value interfere assessment study . 6 . At Screening patient instal pacemaker II III degree atrioventricular block , long QT syndrome QT correct &gt; 500 m 7 . Patients receive blood transfusion blood donation≥ 400 mL severe blood loss least 400 mL within 8 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>SP2086</keyword>
	<keyword>Phase III</keyword>
	<keyword>combination therapy</keyword>
</DOC>